WO2022228577A1 - Nouveau dérivé de benzotropone, son procédé de préparation et son utilisation - Google Patents

Nouveau dérivé de benzotropone, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2022228577A1
WO2022228577A1 PCT/CN2022/090821 CN2022090821W WO2022228577A1 WO 2022228577 A1 WO2022228577 A1 WO 2022228577A1 CN 2022090821 W CN2022090821 W CN 2022090821W WO 2022228577 A1 WO2022228577 A1 WO 2022228577A1
Authority
WO
WIPO (PCT)
Prior art keywords
derivative
novel
cells
novel benzophenone
compound
Prior art date
Application number
PCT/CN2022/090821
Other languages
English (en)
Chinese (zh)
Inventor
郝杰杰
王德
于广利
李海花
Original Assignee
中国海洋大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中国海洋大学 filed Critical 中国海洋大学
Publication of WO2022228577A1 publication Critical patent/WO2022228577A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4

Definitions

  • the invention belongs to the technical field of medicine, and in particular relates to a novel benzophenone derivative and a preparation method and application thereof.
  • Phosphodiesterase is a member of the enzyme family, 11 PDE enzyme families (PDE1-PDE11) are known so far, which differ in their substrate specificity (cAMP, cGMP or both) and their ability to respond to other substrates Dependence on (eg calmodulin). Inhibition of different types of PDE isozymes results in intracellular accumulation of cAMP and/or cGMP, which can be used to treat various inflammation-related diseases.
  • PDE4 is mainly distributed in various inflammatory cells, such as mast cells, macrophages, eosinophils, lymphocytes and epithelial cells, etc. It can increase the intracellular concentration by inhibiting the activity of enzymes, which will help reduce the impact of inflammation on the body. s damage.
  • PDE4 inhibitors In cells important for allergic inflammation (lymphocytes, mast cells, eosinophils, macrophages), the predominant PDE isozyme is also type 4. Therefore, inhibition of PDE4 with suitable inhibitors is regarded as an important starting point for the treatment of various allergic diseases. At present, PDE4 inhibitors have been developed into anti-inflammatory drugs.
  • roflumilast is mainly used for the treatment of inflammation in the lungs, especially asthma and chronic obstructive pulmonary disease; Difamilast is used for the treatment of atopic dermatitis; Prostat is used for the treatment of psoriatic arthritis; at the same time, inhibitors of PDE1, PDE3 and PDE5 have also been used in the treatment of clinical cardiovascular and cerebrovascular diseases, such as vinpocetine, dipyridamole, milrinone, Denafil etc.
  • TNF- ⁇ tumor necrosis factor
  • TNF- ⁇ is an important pro-inflammatory cytokine affecting a variety of biological processes, which can be derived from activated neutrophils, activated T lymphocytes, mast cells, basophils, fibroblasts, endothelial cells, and the brain. astrocyte release. TNF- ⁇ itself activates neutrophils, eosinophils, fibroblasts, and endothelial cells, which in turn release different tissue-destructive mediators.
  • TNF-[alpha] leads to increased levels of other proinflammatory cytokines such as GM-CSF (granulocyte-macrophage colony stimulating factor) or interleukin-8.
  • GM-CSF granulocyte-macrophage colony stimulating factor
  • interleukin-8 interleukin-8.
  • TNF-[alpha] promotes inflammation and catabolism, TNF-[alpha] plays a key role in a variety of diseases such as respiratory inflammation, joint inflammation, endotoxic shock, tissue rejection, AIDS and various other immune diseases. Therefore, PDE4 inhibitors are also suitable for the treatment of TNF- ⁇ -related diseases.
  • the present invention provides a novel benzophenone derivative as well as a preparation method and application thereof.
  • the invention adopts the method of virtual screening combined with computer-aided drug de novo design, and further modifies and transforms the known benzophenone structure, develops a new type of benzophenone derivative, and enhances its targeted inhibition on PDEs
  • Pharmacological experiments have shown that the above derivatives can not only significantly inhibit the activity of phosphodiesterase, but also protect nerve cells, cardiomyocytes and vascular endothelial cells, and reduce the release of TNF- ⁇ , eosinophils or neutrophils. Increased symptoms of inflammation or allergy.
  • the invention provides a novel benzophenone derivative, and the novel benzophenone derivative has the structure of the following general formula:
  • R 1 is selected from straight-chain alkyl consisting of 1-5 carbon atoms, cycloalkyl or cycloalkylmethyl consisting of 3-6 carbon atoms, saturated or unsaturated alkyl of C2-C6, or 1- A fluorine-containing alkyl group consisting of 5 carbon atoms;
  • R 2 is selected from a straight-chain alkyl group consisting of 1-5 carbon atoms, a cycloalkyl group consisting of 3-6 carbon atoms, a cycloalkylmethyl group, a saturated C2-C6 alkyl group or an unsaturated alkyl group, or a fluorine-containing alkyl group consisting of 1-5 carbon atoms;
  • X is selected from carbon or nitrogen.
  • R 1 is selected from -CH 3
  • R 2 is selected from or -CH 3
  • X is selected from C or N.
  • novel benzophenone derivatives are specifically h20, h20-2, h21, h21-2, h22, h23, h24, h24-2, h25, h26, h27, h28, h31, h31-2 , h31-3, h31-5, h32, h33, h34, h35, h36, h36-2, h301, h302, h303, h305, h306, h307, h308, h309, the structural formulas are as follows:
  • novel benzophenone derivatives can effectively inhibit the activity of phosphodiesterase PDEs, inhibit the release of TNF- ⁇ , inhibit the increase of neutrophils, and inhibit the increase of eosinophils.
  • novel benzophenone derivatives can effectively improve cell survival rate.
  • novel benzophenone derivatives can effectively inhibit nerve cell damage induced by A ⁇ aggregates.
  • novel benzophenone derivatives can effectively inhibit the injury of cardiomyocytes induced by CoCl 2 .
  • novel benzophenone derivatives can effectively reverse the vascular endothelial cell damage induced by oxidized low-density lipoprotein ox-LDL.
  • the present invention also provides a preparation method of the novel benzophenone derivative, the preparation method comprising the following steps:
  • h26 h27, h28, h31, h31-2, h31-3, h31-5, h32, h33, h34, h35, h36, h36-2, h301, h302, h303, h305, h306, h307, h308, h309 ;
  • R 1 is selected from -CH 3
  • R 2 is selected from or -CH 3
  • novel benzophenone derivatives also include pharmaceutically acceptable salts thereof, which can be obtained by neutralizing bases with inorganic acids or organic acids by conventional methods.
  • novel benzophenone derivatives also include their R-, S-forms or their mixtures.
  • novel benzophenone derivatives also include its diastereomers.
  • the present invention also provides a pharmaceutical composition containing a therapeutically effective dose of the compound according to any one of claims 1-3 or its stereoisomer, hydrate, metabolite, solvate, pharmacy acceptable salts, co-crystals or prodrugs of the above, and pharmaceutically acceptable carriers, diluents, adjuvants, vehicles or excipients.
  • the present invention also provides the application of the novel benzophenone derivatives in the preparation of phosphodiesterase PDEs and/or TNF- ⁇ inhibitors.
  • novel benzophenone derivatives can effectively inhibit the activity of phosphodiesterase PDEs and the release of TNF- ⁇ .
  • the invention also provides the application of the novel benzophenone derivatives in the preparation of medicines for preventing and treating inflammatory diseases and/or allergic diseases.
  • novel benzophenone derivatives can reduce inflammatory diseases and/or by effectively inhibiting the activity of phosphodiesterase PDEs, inhibiting the release of TNF- ⁇ , and inhibiting the increase of neutrophils or eosinophils. Symptoms of allergic disease.
  • the dosage of the novel benzophenone derivatives for inhibiting the release of TNF- ⁇ is 5 ⁇ M-50 mM.
  • the dosage of the novel benzophenone derivative for inhibiting the increase of neutrophils or eosinophils is 1 mg/kg-500 mg/kg.
  • phosphodiesterase PDEs are PDE4, PDE10, PDE2, PDE5 and PDE3.
  • the phosphodiesterases are PDE4 and PDE10.
  • the inflammatory diseases include chronic obstructive pulmonary disease and pulmonary fibrosis, inflammation caused by TNF- ⁇ release or neutropenia; and the allergic diseases include allergy caused by eosinophilia.
  • Inflammation caused by TNF- ⁇ release includes arthritis, rheumatoid arthritis, rheumatoid spondylitis, pulmonary fibrosis, osteoarthritis, gouty arthritis, gastritis, gastric ulcer, osteoporosis, pus Toxicity, septic shock, Gram-negative sepsis, toxic shock syndrome, respiratory distress syndrome, asthma and other chronic lung diseases, bone resorption disease or transplant rejection or other autoimmunity, lupus erythematosus, multiple Sclerosis, glomerulonephritis and uveitis, insulin-dependent diabetes, and chronic demyelination.
  • Allergies caused by eosinophilia include bronchial asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, psoriasis, eczema, allergic vasculitis, eosinophilic fasciitis, eosinophilic Acidic pneumonia, PIE syndrome (pulmonary infiltrates with eosinophilia), urticaria, ulcerative conjunctivitis, Crohn's disease, psoriasis, and keratosis.
  • the compounds of the present invention are also useful in the treatment of TNF-[alpha]-related infections, including viral and parasitic infections, malaria, leishmaniasis, infection-induced fever, infection-induced muscle pain, AIDS, and cachexia.
  • Inflammation caused by neutropenia includes chronic obstructive pulmonary disease and pulmonary fibrosis.
  • the present invention also provides the application of the novel benzophenone derivatives in the preparation of medicines for preventing and treating diseases of the nervous system and/or cardiovascular system.
  • novel benzophenone derivatives can effectively inhibit A ⁇ aggregates and/or CoCl 2 -induced neuronal and/or cardiomyocyte damage, or effectively reverse oxidized low-density lipoprotein ox-LDL-induced vascular endothelium Cell damage, and then achieve the effect of protecting nerve cells or cardiovascular cells.
  • the diseases of the nervous system and/or cardiovascular system include senile dementia (Alzheimer's disease), memory loss, Parkinson's disease, depression and anxiety, schizophrenia, stroke, intermittent claudication, cardiovascular Injury, arteriosclerosis, heart failure, angina pectoris, hyperlipidemia and hyperglycemia, cerebral ischemic injury disease, benign prostatic hyperplasia, frequent urination, nocturia, as well as striae pain and sexual dysfunction caused by incontinence, urolithiasis.
  • senile dementia Alzheimer's disease
  • memory loss Parkinson's disease
  • Parkinson's disease depression and anxiety
  • schizophrenia stroke
  • intermittent claudication cardiovascular Injury
  • arteriosclerosis heart failure
  • angina pectoris hyperlipidemia and hyperglycemia
  • cerebral ischemic injury disease benign prostatic hyperplasia
  • frequent urination frequent urination
  • nocturia as well as striae pain and sexual dysfunction caused by incontinence, urolithiasis.
  • the medicines are tablets, oral liquids, aerosols, pills, capsules, granules, ointments, drop pills, syrups, powders, granules, tinctures, powder injections or injections, skin creams and gel formulations.
  • the drug is administered orally, parenterally, intravenously, transdermally, topically, by inhalation and intranasally.
  • the dose of the drug is a single dose administered once a day, or divided into two or more doses a day, each time being 0.1-500 mg.
  • the medicine also includes at least one of adjuvant, carrier and additive.
  • the carrier includes calcium carbonate, calcium phosphate, sodium phosphate, lactose, starch, mannitol, alginate, gelatin, guar gum, magnesium stearate, aluminum stearate, methyl cellulose, talc , at least one of highly dispersed silicon dioxide, silicone oil, stearic acid, gelatin, agar, vegetable or animal fats and oils, polyethylene glycol.
  • auxiliary agents include sweeteners, flavoring agents, preservatives, stabilizers, wetting agents, osmotic agents, emulsifiers, coating agents, and cosolvents for controlling osmotic pressure or for buffering At least one of salt, sugar or sugar alcohol and/or viscosity modifier.
  • the additive comprises at least one of tartrate and citrate buffer, ethanol and complexing agent.
  • the additive in order to control the viscosity, can also use liquid polyethylene oxide, microcrystalline cellulose, polyvinylpyrrolidone, dextran or gelatin.
  • Oil suspensions for parenteral or topical administration may contain synthetic or semi-synthetic oils of plants, including their liquid fatty acid esters having 8-22 carbon atoms in the fatty acid chain, including palm acid, lauric acid, tridecanoic acid, heptadecanoic acid, stearic acid, eicosanoic acid, myristic acid, behenic acid, pentadecanoic acid, linoleic acid, elaidic acid, basilic acid , erucic acid or oleic acid, these fatty acids are esterified with monohydric monotrihydric alcohols having 1-6 carbon atoms including methanol, ethanol, propanol, butanol, pentanol or isomers thereof, ethylene glycol alcohol or glycerol; the fatty acid intoxication includes Miglyole, isopropyl myristate, isopropyl palmitate, isopropyl stearate, PEG-6 capric acid
  • solvent as solvent, gel former and cosolvent, use water or alcohol including ethanol or isopropanol, benzyl alcohol, 2-octyldodecanol, polyethylene glycol, phthalates, hexamethylene Diester, Propylene Glycol, Glycerin, Dipropylene Glycol, Tripropylene Glycol, Wax, Methyl Cellosolve, Cellosolve, Esters, Volin, Dioxane, Dimethyl Sulfoxide, Dimethyl Formamide , tetrahydrofuran, cyclohexanone.
  • solvent including ethanol or isopropanol, benzyl alcohol, 2-octyldodecanol, polyethylene glycol, phthalates, hexamethylene Diester, Propylene Glycol, Glycerin, Dipropylene Glycol, Tripropylene Glycol, Wax, Methyl Cellosolve, Cellosolve, Esters, Volin, Dioxan
  • cellulose ethers that can dissolve or swell in water and organic solvents, including hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose or soluble starch, carboxymethyl cellulose Sodium cellulose, polyacrylic acid, polymethacrylic acid and its salts, sodium pullulan glyoxylate, alginic acid or propylene glycol alginate as sodium salt, acacia, xanthan, guar or carrageenan.
  • organic solvents including hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose or soluble starch, carboxymethyl cellulose Sodium cellulose, polyacrylic acid, polymethacrylic acid and its salts, sodium pullulan glyoxylate, alginic acid or propylene glycol alginate as sodium salt, acacia, xanthan, guar or carrageenan.
  • glycerol paraffin with different viscosity
  • triethanolamine triethanolamine
  • collagen or allantoin
  • the medicament can also include surfactants, emulsifiers or wetting agents, including sodium lauryl sulfate, fatty alcohol ether sulfate, disodium N-lauryl- ⁇ -iminodipropionate, polyethylene Oxylated castor oil or sorbitan oleate, sorbitan stearate, polysorbate, cetyl alcohol, lecithin, glycerol-stearate, polyoxyethylene stearate, alkyl Phenol polyglycol ethers, cetyl trimethyl ammonium fluoride or alkyl or dialkyl polyglycol ether orthophosphoric acid ethanolamine salts; stabilizers include montmorillonite or colloidal silica; antioxidants include fertility Phenol or butylated hydroxyanisole; preservatives include parabens.
  • surfactants including sodium lauryl sulfate, fatty alcohol ether sulfate, disodium N-lauryl- ⁇ -
  • the present invention is based on the original structure of marine-derived benzopyridine, and has been transformed to synthesize a novel benzophenone derivative.
  • the derivative has a novel structure, and it is proved by pharmacological experiments that the novel benzophenone derivative has good properties. It can inhibit the activity of PDEs, the release of TNF- ⁇ , neutrophils and eosinophilia, which can reduce a variety of inflammatory diseases or allergic reactions caused by TNF- ⁇ release, neutrophils or eosinophilia. Symptoms of disease, especially COPD and pulmonary fibrosis.
  • novel benzophenone derivatives can also inhibit A ⁇ aggregate-induced neuronal cell damage, inhibit CoCl2 - induced hypoxic damage to neuronal or cardiomyocytes, and effectively reverse ox-LDL-induced vascular endothelial cell damage, thereby Increase the viability of nerve cells or cardiomyocytes, prevent vascular endothelial cells from being damaged by oxidized low-density lipoprotein, and protect nerve cells or cardiovascular cells.
  • the novel benzophenone derivatives of the present invention can have good prevention and treatment effects on various diseases, and the derivatives have good safety and have further development value.
  • novel benzophenone derivative of the present invention has the structure of the following general formula:
  • R 1 is selected from -CH 3
  • R 2 is selected from or -CH 3
  • X is selected from C or N.
  • R 1 -CH 3
  • R 2 in the synthetic general structure
  • PDE4 activity was determined in enzymatic preparations of rat polymorphonuclear lymphocytes (PMNL) and PDE2, PDE3, PDE5, PDE10 activities were determined with PDE from isolated platelets. Extracted rat blood was prevented from clotting with citrate; platelet-rich plasma in the supernatant was separated from erythrocytes and leukocytes by centrifugation at room temperature; platelets were lysed by sonication and reserved for PDE3 and PDE5 assays used in.
  • the cytoplasmic platelet fraction was purified by NaCl gradient on an anion exchange column to obtain the PDE2 peak for the assay; after sedimentation by dextran, PMNL cells for PDE4 assay were isolated by Ficoll gradient centrifugation . After 2 washes of PMNL cells, residual erythrocytes were removed by adding 10 mL of hypotonic lysis buffer and lysed at 4°C for 6 min. The still intact PMNL cells were washed twice with PBS, lysed by sonication, and centrifuged at high speed for 1 h at 4°C. The obtained supernatant contained the cytoplasmic fraction of PDE4 for use in the following assays for PDE4, PDE10, Feedstock for enzymes in PDE5, PDE2 and PDE3 assays.
  • phosphodiesterase activity assay kit purchased from Abcam, product number ab13940, PDE Activity Assay kit, Colorimetric
  • the protease prepared by the method can be separated and tested strictly according to the operating instructions: first add 20 microliters of cAMP substrate, then add 15 microliters of assay buffer, then add 10 microliters of 5' nucleotidase, and mix well. Add an appropriate concentration of the test compound, then add the PDE enzyme that has been extracted and purified, and incubate at 30°C for 30 minutes. Finally, add Green Assay reagent to detect the decomposed phosphate ions. After mixing for 30 minutes, the color is uniform. By measuring OD 620nm To calculate the inhibitory activity of compounds against PDE enzymes.
  • Example 3 Novel benzophenone derivatives inhibit the release of TNF- ⁇ from nasal polyp cells
  • the resulting mixture of cells was filtered, washed by repeated centrifugation in culture solution, passively sensitized by addition of human-derived IgE, and cells were
  • the suspension was diluted to a concentration of 2 million cells/mL in RPMI 1640 (supplemented with antibiotics, 10% fetal bovine serum, 2 mM glutamine and 25 mM Hepes).
  • the suspension was distributed on 6-well cell culture plates (1 ml/well).
  • Example 4 Novel benzophenone derivatives inhibit eosinophilia in a rat allergic model
  • mice After the experimental mice were grouped, they were sensitized on the first day: the rats in the blank group were given intraperitoneal injection of 1 ml of normal saline, while the model group was given intraperitoneal injection of 1 ml of sensitization solution; In the nebulizing box of the same size, the blank group was given 6 ml of normal saline to stimulate, and the model group was given 6 ml of 5% V-grade ovalbumin solution, once a day, for 30 minutes each time, for 10 days. Test compounds were administered intraperitoneally or orally as a suspension in 10% polyethylene glycol 300 and 0.5% 5-hydroxyethylcellulose 2 hours prior to allergen challenge. The control group is treated with vehicle depending on the administration form of the test compound.
  • the limbs of the rats were immobilized, the neck was disinfected with 75% alcohol, the trachea was fully exposed, and a tracheal intubation needle was inserted near the throat (the needle was slightly flattened), and the needle was inserted into a certain position, never going beyond the bifurcation of the trachea;
  • Leukocytes are an important type of cells in the immune process, and cell differential counting can effectively analyze the changes in the proportion of leukocytes in the bronchoalveolar lavage fluid (BALF).
  • BALF bronchoalveolar lavage fluid
  • the inflammatory cells infiltrating the rat bronchus were mainly lymphocytes and eosinophils.
  • Lymphocytes can expand the inflammatory response of eosinophils on the bronchial mucosa, and with the increase of eosinophils, they will increase their aggregation, activation and interaction with other inflammatory cells, inflammatory mediators, and cytokines in the lung. further aggravate allergies.
  • the novel benzophenone derivatives of the present invention can effectively inhibit the increase of eosinophils, thereby reducing the aggregation of inflammatory cells and their interactions with other cells, and finally reducing allergic reactions, and is suitable for preventing and treating eosinophils caused by eosinophils. Increased induced related diseases.
  • Example 5 Novel benzophenone derivatives inhibit lipopolysaccharide (LPS)-induced neutropenia
  • the inhibitory effect of the compound prepared in Example 1 on pulmonary neutrophil infiltration was tested in male Wistar rats (200 ⁇ 20 g). On the day of the experiment, animals were individually placed in an open 1 L plexiglass box attached to a head-nose exposure device. Animals were exposed to an aerosol (LPS challenge) of a lipopolysaccharide suspension (LPS 100 ⁇ g/mL in PBS containing 0.1% hydroxylamine) for 45 minutes, and the standard control was 0.1% hydroxylamine Aerosol spray of PBS solution for 45 min. Six hours after LPS challenge, a large number of neutrophils migrated into the lungs of animals.
  • LPS challenge a lipopolysaccharide suspension
  • Each compound tested was administered orally as a suspension in 10% polyethylene glycol 300 and 0.5% 5-hydroxyethylcellulose 2 hours prior to LPS challenge.
  • the control group was treated with vehicle depending on the administration form of the test article.
  • the limbs of the rats were immobilized, the neck was disinfected with 75% alcohol, the trachea was fully exposed, and a tracheal intubation needle was inserted near the throat (the needle was slightly flattened), and the needle was inserted into a certain position, never going beyond the bifurcation of the trachea;
  • Repeated lavage with 2 mL of pre-cooled PBS for 3 times collected bronchoalveolar lavage fluid into EP tubes, centrifuged at 1000 rpm at 4 °C, collected cells, stained with Wright-Giemsa, and counted cells under a microscope.
  • the novel benzophenone derivatives of the present invention can effectively inhibit the increase of neutrophils, thereby relieving the symptoms caused by neutropenia, and thus are suitable for preventing and treating diseases related to neutropenia.
  • Example 6 Protective effect of novel benzophenone derivatives on A ⁇ aggregate-induced neuronal injury
  • Example 1 Taking the cell viability without A ⁇ 1-42 as a negative control, the inhibitory effect of the compound prepared in Example 1 on A ⁇ -induced neurotoxicity was observed. Cultured in a 96-well plate, placed in a constant temperature cell incubator for 24 hours, and then added A ⁇ protein oligomers that had aggregated in advance. After 2 hours, each compound group was added with the compound solution in each well at a concentration of 50 ⁇ mol/L. The same amount of sterile water was incubated in the incubator for 24h. After the end, the cell viability was measured by MTT method. The experiment was repeated three times in three parallels each time.
  • Example 7 Protective effect of novel benzophenone derivatives on CoCl2 - induced hypoxic injury of neurons and cardiomyocytes
  • Example 8 Inhibitory effect of novel benzophenone derivatives on oxidative low-density lipoprotein (ox-LDL)-induced vascular endothelial cell injury
  • ox-LDL can induce atherosclerosis by inducing vascular endothelial damage.
  • Vascular endothelial cells HUVEC were inoculated into MEM complete medium, and the group without oxidized low-density lipoprotein ox-LDL was used as a negative control to observe the protective effect of each compound on ox-LDL-induced vascular endothelial atherosclerotic injury.
  • the details are as follows: inoculate HUVEC cells in MEM or DMEM complete culture medium, place them in a 96-well plate for culture, put them in a constant temperature cell incubator for 24 hours, and add the pre-dissolved induction solution containing ox-LDL. , 50 ⁇ M benzophenone derivatives were added to each well, and the group without ox-LDL was used as a negative control. After the end, the content of IL-6 inflammatory factor was detected by ELISA.
  • Example 9 The effect of new structural benzophenone derivatives on alveolar neutrophil infiltration in COPD model of COPD induced by smoking combined with LPS respiratory instillation
  • mice were randomly divided into 7 groups with 10 mice in each group, namely blank group, model group, h21 drug group, h31-3 drug group, h28 drug group, h303 drug group and positive drug group.
  • cigarettes were put into a smoke generator (30 cigarettes/time), and all mice were placed in a poisoning box (80 cm x 80 cm x 80 cm in size). Except for the blank group, after the other groups lit cigarettes, the smoke was injected into the poisoning box through the automatic suction of the syringe to make the mice smoke, twice a day in the morning and evening, each time lasted 30 minutes, with an interval of more than 4 hours, and smoked continuously for 40 minutes. During this process, make sure to burn all the cigarettes within 5 minutes.
  • mice in the other groups were anesthetized by intraperitoneal injection of 10% chloral hydrate solution. /kg of LPS, the mice were quickly rotated upright for 20 s after completion, so that the LPS solution was evenly distributed in the lung lobes, and then the mice wounds were sutured.
  • Mice in the drug treatment group were fed 30 mg/kg (body weight) of h21, h31-3, h28 or h303 every day, and the mice in the positive drug group were fed 5 mg/kg (body weight) of roflumilast every day for 45 days. All mice were fed normally.
  • mice All the tested animals were anesthetized by intraperitoneal injection of sodium pentobarbital solution on the 45th day after administration, lay supine on the operating table, fixed their limbs, disinfected their necks with 75% alcohol, and then fully exposed the mice Trachea, insert a 18g tracheal intubation needle near the throat (the needle is slightly ground), insert the needle into a certain position, do not exceed the tracheal bifurcation; repeat lavage with 4°C sterile saline for 3 times, collect the lavage fluid, After centrifugation at 1800rpm/min for 5min, the pellet was suspended with PBS, smeared, stained with Wright-Gimes, and the neutrophils were observed and counted with a microscope, and the number of neutrophils in 100 nucleated cells was observed and calculated. Percentage of neutrophils.
  • neutrophils During the pathogenesis of COPD, various mediator factors can promote the migration and aggregation of neutrophils, and at the same time, neutrophils release oxidative metabolites, proteases, and cytokines, which cause damage to local tissues and cause peripheral airway damage. Chronic injury also leads to the imbalance of protease-antiprotease and causes emphysema, thereby promoting the occurrence and development of COPD. Therefore, neutrophils are an important indicator for evaluating COPD.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un nouveau dérivé de benzotropone, son procédé de préparation et son utilisation. Le nouveau dérivé de benzotropone possède une structure telle que représentée par les formules générales (I) ou (II), dans lesquelles R1 et R2 sont tous deux choisis parmi un groupe alkyle linéaire constitué de 1 à 5 atomes de carbone, un groupe cycloalkyle ou un groupe cycloalcoylméthyl constitué de 3 à 6 atomes de carbone, un groupe alkyle saturé ou insaturé en C2-C6, ou un groupe alkyle contenant du fluor constitué de 1 à 5 atomes de carbone, et X est choisi parmi le carbone ou l'azote. La présente invention démontre, au moyen d'expériences pharmacologiques, que le nouveau dérivé de benzotropone présente des effets d'inhibition de l'activité de la phosphodiestérase PDES, la libération de TNF-α, la neutrophilie ou l'éosinophilie, et peut également protéger des cellules nerveuses, des cellules myocardiques et des cellules endothéliales vasculaires, a une bonne innocuité, et présente ainsi une importance de développement significative.
PCT/CN2022/090821 2021-04-30 2022-04-30 Nouveau dérivé de benzotropone, son procédé de préparation et son utilisation WO2022228577A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110489076.5A CN115260090A (zh) 2021-04-30 2021-04-30 一种新型苯并酮类衍生物及其制备方法和应用
CN202110489076.5 2021-04-30

Publications (1)

Publication Number Publication Date
WO2022228577A1 true WO2022228577A1 (fr) 2022-11-03

Family

ID=83746124

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/090821 WO2022228577A1 (fr) 2021-04-30 2022-04-30 Nouveau dérivé de benzotropone, son procédé de préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN115260090A (fr)
WO (1) WO2022228577A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109705034A (zh) * 2017-10-25 2019-05-03 中国海洋大学 一种吡啶生物碱类化合物的合成方法及其应用
WO2020115231A1 (fr) * 2018-12-06 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions destinées au traitement des voies respiratoires atteintes de mucoviscidose

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109705034A (zh) * 2017-10-25 2019-05-03 中国海洋大学 一种吡啶生物碱类化合物的合成方法及其应用
WO2020115231A1 (fr) * 2018-12-06 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions destinées au traitement des voies respiratoires atteintes de mucoviscidose

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAO SUFAN, XU QINLONG, LI JIAMING, CHU ZHAOXING, HE GUANGWEI, LIN GAOFENG, ZHU ZHENWEI, CUI YONG, MO JIAJIA, GUO JING, ZHAO YAN: "Design, Synthesis, and Biological Evaluation of Novel PDE-4 Inhibitors", CHINESE JOURNAL OF ORGANIC CHEMISTRY, vol. 38, no. 2, 11 October 2017 (2017-10-11), CN , pages 478 - 485, XP055980270, ISSN: 0253-2786, DOI: 10.6023/cjoc201705042 *
TURNER MARK J., LUO YISHAN, THOMAS DAVID Y., HANRAHAN JOHN W.: "The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, vol. 318, no. 5, 1 May 2020 (2020-05-01), US , pages 908 - 920, XP055980248, ISSN: 1040-0605, DOI: 10.1152/ajplung.00285.2019 *
ZHOU HAIBO, LI LIYUAN, WU CHONGMING, KURTÁN TIBOR, MÁNDI ATTILA, LIU YANKAI, GU QIANQUN, ZHU TIANJIAO, GUO PENG, LI DEHAI: "Penipyridones A–F, Pyridone Alkaloids from Penicillium funiculosum", JOURNAL OF NATURAL PRODUCTS, vol. 79, no. 7, 22 July 2016 (2016-07-22), US , pages 1783 - 1790, XP055975240, ISSN: 0163-3864, DOI: 10.1021/acs.jnatprod.6b00218 *

Also Published As

Publication number Publication date
CN115260090A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
JP3842043B2 (ja) 新規ヒドロキシインドール、ホスホジエステラーゼ４のインヒビタとしてのその使用及びその製法
ITRM940706A1 (it) "isochinoline"
EP1330455B1 (fr) Nouveaux 7-azaindoles, leur utilisation en tant qu'inhibiteurs de la phosphodiesterase 4 et leur procede de production
JP2004530705A (ja) 閉塞性気道疾患及びその他の炎症性疾患を治療するためのｐｄｅ４インヒビター及びチオトロピウム又はその誘導体の組み合わせ
EP0641344A1 (fr) Xanthines 8-substituees utilisees en tant qu'inhibiteurs de la phosphodiesterase
US9487492B2 (en) Dibenzothiazepine derivatives and their use in the treatment of CNS disorders
WO2022228577A1 (fr) Nouveau dérivé de benzotropone, son procédé de préparation et son utilisation
CN111807983B (zh) 一种肉桂酸衍生物及其制备方法
CN115073329B (zh) 一种新型益母草碱衍生物及其制备方法和应用
WO2022237798A1 (fr) Dérivé de benzoylguanidine, son procédé de préparation et son utilisation
CN115197190A (zh) 一种新型植物黄酮衍生物及其制备方法和应用
CN115197191A (zh) 一种新型中药黄酮衍生物及其制备方法和应用
US20180353511A1 (en) Use of MTAP Inhibitors for the Treatment of Lung Disease
US20060293362A1 (en) Nitro-substituted hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
KR20060021830A (ko) 7-아자인돌 및 치료제로서의 이의 용도
CN113330020B (zh) 用于治疗神经变性疾病的2-氟代的胆汁酸
SK14812001A3 (sk) Maduraftalazínové deriváty a ich použitie ako inhibítorov prozápalových cytokínov
CN115260141A (zh) 一种二苯酮类衍生物及其制备方法和应用
JP2012532150A (ja) １３ａ−（Ｓ）脱酸チロホリニンの塩、医薬組成物と用途
CN115073409A (zh) 一种新型淫羊霍素衍生物及其制备方法和应用
DE10053275A1 (de) Neue 7-Azaindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
JP6602297B2 (ja) ジフェニルオキシアルキルアミン誘導体およびアリールオキシアルキルアミン誘導体、薬学的組成物、慢性肺炎症性疾患を治療、予防、または阻止するための前記薬学的組成物の使用、ならびにそのような疾患を治療または予防するための方法
WO2017133429A1 (fr) Terpinéol et procédé de préparation et application correspondants
TW201618757A (zh) 具抗發炎活性之化合物，組合物及製備方法
JPH09503524A (ja) ロイコトリエンｄ４拮抗薬としての二環式カルバメート

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22795046

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22795046

Country of ref document: EP

Kind code of ref document: A1